1. Home
  2. VRCA vs KLRS Comparison

VRCA vs KLRS Comparison

Compare VRCA & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRCA
  • KLRS
  • Stock Information
  • Founded
  • VRCA 2013
  • KLRS 2019
  • Country
  • VRCA United States
  • KLRS United States
  • Employees
  • VRCA N/A
  • KLRS N/A
  • Industry
  • VRCA Biotechnology: Pharmaceutical Preparations
  • KLRS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • VRCA Health Care
  • KLRS Health Care
  • Exchange
  • VRCA Nasdaq
  • KLRS Nasdaq
  • Market Cap
  • VRCA 58.0M
  • KLRS 57.5M
  • IPO Year
  • VRCA 2018
  • KLRS N/A
  • Fundamental
  • Price
  • VRCA $0.49
  • KLRS $6.99
  • Analyst Decision
  • VRCA Hold
  • KLRS Buy
  • Analyst Count
  • VRCA 5
  • KLRS 1
  • Target Price
  • VRCA $6.00
  • KLRS N/A
  • AVG Volume (30 Days)
  • VRCA 614.0K
  • KLRS 52.0K
  • Earning Date
  • VRCA 05-12-2025
  • KLRS 05-15-2025
  • Dividend Yield
  • VRCA N/A
  • KLRS N/A
  • EPS Growth
  • VRCA N/A
  • KLRS N/A
  • EPS
  • VRCA N/A
  • KLRS N/A
  • Revenue
  • VRCA $7,566,000.00
  • KLRS N/A
  • Revenue This Year
  • VRCA $127.58
  • KLRS N/A
  • Revenue Next Year
  • VRCA $88.06
  • KLRS N/A
  • P/E Ratio
  • VRCA N/A
  • KLRS N/A
  • Revenue Growth
  • VRCA 47.66
  • KLRS N/A
  • 52 Week Low
  • VRCA $0.38
  • KLRS $5.87
  • 52 Week High
  • VRCA $11.41
  • KLRS $24.15
  • Technical
  • Relative Strength Index (RSI)
  • VRCA 46.71
  • KLRS N/A
  • Support Level
  • VRCA $0.38
  • KLRS N/A
  • Resistance Level
  • VRCA $0.59
  • KLRS N/A
  • Average True Range (ATR)
  • VRCA 0.09
  • KLRS 0.00
  • MACD
  • VRCA 0.01
  • KLRS 0.00
  • Stochastic Oscillator
  • VRCA 40.52
  • KLRS 0.00

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Share on Social Networks: